Novel therapeutics in hypertriglyceridemia

Current Opinion in Lipidology
Steven E Gryn, Robert A Hegele

Abstract

We provide an overview of recent advances in the therapy of hypertriglyceridemia, focusing on several new therapies with potential for treating of familial chylomicronemia, other forms of hypertriglyceridemia, and for triglyceride-lowering in patients with other lipid disorders. Newer triglyceride-lowering modalities under evaluation include gene therapy for lipoprotein lipase deficiency (alipogene tiparvovec), and antisense oligonucleotides against mRNA for apolipoproteins B (mipomersen) and C3 (volanesorsen, ISIS 304801). Other potential therapies include small molecule inhibitors of microsomal triglyceride transfer protein (lomitapide) and diacylglycerol acyltransferase-1 (pradigastat), and a monoclonal antibody against angiopoietin-like protein 3 (REGN1500). There is also renewed interest in omega-3 fatty acids, and in developing potent and selective agonists of peroxisome proliferator-activated receptors. Several promising triglyceride-lowering therapies are at various stages of development; a few are even available in some markets. Although existing data suggest good biochemical efficacy, data on long-term clinical outcomes are still limited. For some therapies, cost will be an important consideration, and use will likely...Continue Reading

References

Dec 1, 1986·Journal of the American College of Cardiology·P L CannerW Friedewald
Sep 20, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Erik S StroesJan Albert Kuivenhoven
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
May 11, 2010·Lancet·UNKNOWN Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors CollaborationJohn Danesh
Oct 15, 2010·The New England Journal of Medicine·Kiran MusunuruSekar Kathiresan
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Mar 23, 2012·The Journal of Clinical Endocrinology and Metabolism·André C CarpentierDaniel Gaudet
Jul 31, 2013·Expert Opinion on Investigational Drugs·Paul Lee, Robert A Hegele
Dec 25, 2013·JAMA Internal Medicine·Frank M SacksRobert A Hegele
Apr 1, 2014·JAMA : the Journal of the American Medical Association·A Michael LincoffUNKNOWN AleCardio Investigators
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·Robert A HegeleUNKNOWN European Atherosclerosis Society Consensus Panel
Jun 19, 2014·The New England Journal of Medicine·Jacy CrosbySekar Kathiresan
Jun 19, 2014·The New England Journal of Medicine·Anders Berg JørgensenAnne Tybjærg-Hansen
Jul 2, 2014·Biochemical and Biophysical Research Communications·Mikael LarssonGunilla Olivecrona
Jul 12, 2014·The New England Journal of Medicine·Martin J LandrayJane Armitage
Sep 13, 2014·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Rémy HanfBart Staels
Dec 4, 2014·The New England Journal of Medicine·Daniel GaudetJoseph L Witztum
Jan 22, 2015·Expert Opinion on Investigational Drugs·Zhong-Min LiuBrian Tomlinson
Mar 4, 2015·Nature Reviews. Endocrinology·Amanda J Brahm, Robert A Hegele
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators
Mar 17, 2015·The New England Journal of Medicine·Marc S SabatineUNKNOWN Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators

❮ Previous
Next ❯

Citations

May 25, 2016·Current Cardiology Reports·Michel Farnier
Oct 7, 2016·Postgraduate Medicine·Pamela A Kushner, Michael E Cobble
Oct 28, 2016·Expert Opinion on Investigational Drugs·Amanda J Brahm, Robert A Hegele
Aug 24, 2017·Praxis·Arnold von Eckardstein
Jul 16, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Jong-Gil ParkAnn-Hwee Lee
Feb 1, 2019·Circulation Research·Robert A Hegele, Sotirios Tsimikas
Nov 26, 2019·European Heart Journal·Ulrich LaufsRobert A Hegele
Sep 29, 2017·Current Opinion in Lipidology·Anthony C Keech, Alicia J Jenkins
Oct 14, 2017·Journal of the Association for Research in Otolaryngology : JARO·Abhilash PonnathJennifer J Lentz
Nov 3, 2016·Current Opinion in Lipidology·Steven E Gryn, Robert A Hegele
Jul 30, 2020·Minerva gastroenterologica e dietologica·Nicolò De PretisLuca Frulloni
May 12, 2019·Journal of Internal Medicine·Amanda J BerberichRobert A Hegele
Aug 8, 2018·United European Gastroenterology Journal·Nicolò de PretisLuca Frulloni
Aug 28, 2018·BioMed Research International·Rajat Garg, Tarun Rustagi
Apr 1, 2016·Current Opinion in Lipidology·Gunilla Olivecrona
Nov 3, 2016·Current Opinion in Lipidology·Dick C ChanGerald F Watts
May 14, 2021·Journal of Atherosclerosis and Thrombosis·Hiroaki OkazakiMariko Harada-Shiba

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
antisense oligonucleotide
FCS
biopsy

Clinical Trials Mentioned

NCT01514461
NCT01589237
NCT02211209
NCT02300233
NCT02107872
NCT01749878
NCT02265952
NCT01492361

Related Concepts

Related Feeds

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Related Papers

Progress in Lipid Research
Amirhossein SahebkarGerald F Watts
Journal of Cardiovascular Pharmacology and Therapeutics
Mfon Ewang-Emukowhate, Anthony S Wierzbicki
International Journal of Clinical Practice
Anthony S WierzbickiAdie Viljoen
Clinical Medicine : Journal of the Royal College of Physicians of London
Anthony S WierzbickiMfon Ewang-Emukowhate
Expert Review of Cardiovascular Therapy
Jing PangGerald F Watts
© 2022 Meta ULC. All rights reserved